Get the Stockscreener App
17.77
5.02%
0.85
Arcturus Therapeutics Holdings Inc stock is traded at $17.77, with a volume of 433.12K.
It is up +5.02% in the last 24 hours and up +8.29% over the past month.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.
See More
Previous Close:
$16.92
Open:
$17.24
24h Volume:
433.12K
Relative Volume:
1.03
Market Cap:
$481.34M
Revenue:
$157.75M
Net Income/Loss:
$-29.73M
P/E Ratio:
-15.32
EPS:
-1.16
Net Cash Flow:
$-21.00M
1W Performance:
-1.55%
1M Performance:
+8.29%
6M Performance:
-18.78%
1Y Performance:
-49.63%
1-Day Range:
$16.63
$17.86
1-Week Range:
$16.54
$19.25
52-Week Range:
$14.30
$45.00
Arcturus Therapeutics Holdings Inc Stock (ARCT) Company Profile
Name
Arcturus Therapeutics Holdings Inc
Sector
Industry
Phone
(858) 900-2660
Address
10628 SCIENCE CENTER DRIVE, SAN DIEGO, CA
Compare ARCT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ARCT
Arcturus Therapeutics Holdings Inc
|
17.77 | 481.34M | 157.75M | -29.73M | -21.00M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arcturus Therapeutics Holdings Inc Stock (ARCT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-25 | Initiated | BTIG Research | Buy |
| Aug-12-24 | Initiated | Leerink Partners | Outperform |
| Dec-13-23 | Initiated | Canaccord Genuity | Buy |
| Jul-24-23 | Initiated | William Blair | Outperform |
| May-11-23 | Upgrade | H.C. Wainwright | Neutral → Buy |
| Nov-14-22 | Resumed | Wells Fargo | Overweight |
| Nov-10-22 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Nov-03-22 | Upgrade | Citigroup | Neutral → Buy |
| Nov-02-22 | Upgrade | Barclays | Underweight → Equal Weight |
| Aug-10-22 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Jul-19-22 | Resumed | Cantor Fitzgerald | Overweight |
| May-11-22 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Apr-21-22 | Downgrade | Citigroup | Buy → Neutral |
| Jan-31-22 | Upgrade | Raymond James | Underperform → Mkt Perform |
| Aug-12-21 | Downgrade | Raymond James | Mkt Perform → Underperform |
| Aug-11-21 | Downgrade | Goldman | Neutral → Sell |
| Aug-10-21 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Jul-02-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Jun-21-21 | Downgrade | Barclays | Equal Weight → Underweight |
| Jun-04-21 | Resumed | Robert W. Baird | Neutral |
| Feb-17-21 | Downgrade | B. Riley Securities | Neutral → Sell |
| Jan-19-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-15-21 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-07-21 | Initiated | Wells Fargo | Overweight |
| Dec-29-20 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-29-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-29-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-29-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Dec-23-20 | Downgrade | ROTH Capital | Buy → Sell |
| Dec-08-20 | Reiterated | B. Riley Securities | Buy |
| Dec-07-20 | Reiterated | B. Riley Securities | Buy |
| Oct-26-20 | Initiated | Barclays | Overweight |
| Oct-06-20 | Initiated | Citigroup | Buy |
| Aug-26-20 | Initiated | Piper Sandler | Overweight |
| Jul-30-20 | Resumed | ROTH Capital | Buy |
| Jul-16-20 | Initiated | Raymond James | Outperform |
| Jul-13-20 | Initiated | B. Riley FBR | Buy |
| Jun-09-20 | Downgrade | WBB Securities | Buy → Hold |
| Feb-11-20 | Initiated | Robert W. Baird | Outperform |
| Feb-07-20 | Initiated | Guggenheim | Buy |
| Feb-06-20 | Initiated | Guggenheim | Buy |
| Apr-05-19 | Initiated | H.C. Wainwright | Buy |
| Sep-20-18 | Upgrade | WBB Securities | Buy → Strong Buy |
| Jan-22-18 | Initiated | Chardan Capital Markets | Buy |
View All
Arcturus Therapeutics Holdings Inc Stock (ARCT) Latest News
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Short Interest Down 9.9% in January - MarketBeat
Empire Life Investments Inc. Purchases 128,771 Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
HC Wainwright Reaffirms Buy Rating for Arcturus Therapeutics (NASDAQ:ARCT) - MarketBeat
The week in pharma: action, reaction and insight – week to February 14 - The Pharma Letter
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $65.00 Consensus Target Price from Analysts - Defense World
Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $65.00 - MarketBeat
Sumitomo Mitsui Trust Group Inc. Has $35.04 Million Position in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - MarketBeat
EC approves CSL and Arcturus’ Kostaive - The Pharma Letter
CSL and Arcturus Therapeutics Announces Marketing Authorization Grant by European Commission Marketing Authorization for Kostaive (Arct-154), A Self-Amplifying Mrna Covid-19 Vaccine - Marketscreener.com
Breaking Down Arcturus Therapeutics: 5 Analysts Share Their Views - Benzinga
ARCTArcturus Therape Latest Stock News & Market Updates - StockTitan
Arcturus Therapeutics Says EU Commission Approves COVID-19 Vaccine Kostaive - Marketscreener.com
EU Grants Marketing Authorization For KOSTAIVE To CSL And Arcturus Therapeutics - Nasdaq
Revolutionary COVID Vaccine Breakthrough: New Technology Shows Year-Long Immunity in EU Approval - StockTitan
Revolutionary COVID Vaccine Breakthrough: EU Approves KOSTAIVE with Year-Long Immunity Power - StockTitan
European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - The Malaysian Reserve
Selling Arcturus Therapeutics Holdings Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders - Simply Wall St
SG Americas Securities LLC Has $203,000 Stake in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) - Defense World
Arcturus Therapeutics names Moncef Slaoui as Chair Designate - MSN
State Street Corp Reduces Holdings in Arcturus Therapeutics Holdings Inc - GuruFocus.com
Arcturus Therapeutics names Moncef Slaoui as Chair Designate By Investing.com - Investing.com Australia
Short Interest in Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Increases By 8.6% - MarketBeat
Global mRNA Vaccines and Therapeutics Market is expected - openPR
Arcturus Therapeutics Appoints Moncef Slaoui Chair Designate -February 04, 2025 at 10:40 am EST - Marketscreener.com
Arcturus Therapeutics' SWOT analysis: mRNA innovator's stock faces pivotal year - MSN
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire
Arcturus Therapeutics (NASDAQ:ARCT) Now Covered by Analysts at BTIG Research - MarketBeat
Japan's COVID Vaccine Independence: Meiji Gets Green Light for Local KOSTAIVE Production - StockTitan
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - BioSpace
BTIG Research Begins Coverage on Arcturus Therapeutics (NASDAQ:ARCT) - Defense World
ARCT (Arcturus Therapeutics Holdings) Cash-to-Debt : 8.06 (As of Sep. 2024) - GuruFocus.com
BTIG Initiates Coverage of Arcturus Therapeutics Holdings (ARCT) with Buy Recommendation - Nasdaq
Arcturus: Downgrading As mRNA Promise Meets Market Reality (NASDAQ:ARCT) - Seeking Alpha
Demystifying Arcturus Therapeutics: Insights From 5 Analyst Reviews - Benzinga
BTIG Initiates Arcturus Therapeutics Holdings at Buy With $41 Price Target -January 28, 2025 at 07:27 am EST - Marketscreener.com
Arcturus Therapeutics to Present at the Investor Summit on December 17th in Philadelphia. - ACCESS Newswire
Leerink Partnrs Has Positive Outlook of ARCT FY2024 Earnings - Defense World
What is Leerink Partnrs' Forecast for ARCT FY2024 Earnings? - MarketBeat
Cantor Fitzgerald Forecasts ARCT FY2025 Earnings - Defense World
Q3 Earnings Estimate for ARCT Issued By Leerink Partnrs - Defense World
Q3 Earnings Forecast for ARCT Issued By Leerink Partnrs - MarketBeat
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Receives $66.75 Consensus Target Price from Analysts - Defense World
Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) Sees Significant Increase in Short Interest - Defense World
Arcturus Therapeutics Holdings Inc Stock (ARCT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
3.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):